SNY · Sanofi

Sanofi's 6-K filing highlights multiple positive developments across its pipeline, signaling potential revenue growth from expanded indications and market authorizations. Exhibit 99.1 details the COMPARE study results where Nuvaxovid demonstrated superior tolerability over Moderna's mNEXSPIKE, with key metrics including 8.0% lower risk of systemic reactions (95% CI: 4.0%-12%; p<0.001), 18% lower moderate-to-severe systemic symptoms, and 20% lower local symptoms. Participants receiving Nuvaxovid were nearly twice as likely to choose it again, addressing vaccine hesitancy amid ongoing COVID-19 burden. Sanofi holds market authorization for Nuvaxovid in US, EU, UK, with expansions planned to UK, Germany, Canada from 2026. Exhibit 99.2 notes FDA extension of Sarclisa SC review to July 23, 2026, potentially introducing the first on-body injector anticancer treatment if approved, following CHMP positive opinion. Exhibit 99.3 announces Tzield sBLA approval expanding to children aged 1+ with stage 2 T1D, supported by PETITE-T1D safety data, positioning it as the first disease-modifying therapy for this group. Exhibit 99.4 covers Dupixent approval with Regeneron for CSU in children 2-11 years uncontrolled on H1AH, based on LIBERTY-CUPID studies showing itch and urticaria reductions, marking the fifth type 2 inflammation indication in young children. Exhibit 99.5 reports CHMP positive opinion for Cenrifki in non-relapsing SPMS, based on HERCULES showing delayed disability progression via brain-penetrant BTK inhibition. These updates underscore Sanofi's immunology and neurology focus, with potential to broaden patient access and drive commercial uptake.